Dr Rachael Zemek completed her PhD at the University of Western Australia and the National Centre of Asbestos Related Diseases in 2019. Here her project focused on the
divergent response to immune checkpoint blockade therapy for cancer, with the aim to identify biomarkers of response, as well as a way to pharmaceutically modulate the tumour to increase response rates. Rachael now works as a post-doctoral researcher in the Sarcoma Group at the Telethon Kids Institute. Here she is extending her research to target immune checkpoint resistant sarcoma tumours.
